Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305141 | 0.84 | CETP (0.60) | CETPPTGDR2LMNALTA4HKDM4E | |
| SCHEMBL11748397 | 0.79 | LMNA (0.59) | PTGDR2LMNAALOX5KDM4EALDH1A1 | |
| SCHEMBL11750227 | 0.79 | LMNA (0.59) | PTGDR2LMNAALOX5KDM4EALDH1A1 | |
| SCHEMBL1304150 | 0.78 | CETP (1.00) | CETPLMNAALOX5ALDH1A1NPSR1 | |
| SCHEMBL1303840 | 0.77 | CETP (0.53) | CETPPTGDR2ALOX5LTA4HALDH1A1 | |
| Hydrochloric Acid SCHEMBL1304192 | 0.77 | CETP (0.76) | CETPPTGDR2ALDH1A1NPSR1 | |
| SCHEMBL27925087 | 0.76 | NPC1 (0.54) | CETPPTGDR2LTA4HALDH1A1 | |
| SCHEMBL1302668 | 0.76 | ADORA1 (0.69) | PTGDR2LMNANPSR1L3MBTL1 | |
| SCHEMBL1303816 | 0.75 | ADORA1 (0.66) | PTGDR2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL1302539 | 0.75 | CETP (0.77) | CETPPTGDR2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772488-B1 | 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-11-02 | — | — | EP | disclosed |
| EP-2772488-A1 | 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L. A. China (CN) | 2014-09-03 | — | — | EP | disclosed |
| US-8053581-B2 | Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China (CN) | 2011-11-08 | — | — | US | disclosed |
| US-20090298832-A1 | TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2009-12-03 | — | — | US | disclosed |
| EP-2042494-A1 | 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298832-A1 | TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF | CETP, PLTP, MTTP | CETP 1/4885PTGDR2 2425/4885LMNA 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.